Amneal Pharmaceuticals Inc (AMRX) |
|
4.98 -0.12 (-2.35%)
|
02-25 12:13 |
|
Open: |
5.05 |
Pre. Close: |
5.1 |
|
High:
|
5.14 |
Low:
|
4.96 |
|
Volume:
|
357,942 |
Market Cap:
|
735M |
|
|
|
|
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.187 - 5.216 |
5.216 - 5.243 |
|
Low:
|
4.756 - 4.793 |
4.793 - 4.826 |
|
Close:
|
5.045 - 5.1 |
5.1 - 5.15 |
|
Technical analysis |
as of: 2021-02-25 11:41:54 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 6.53 One year: 7.22 |
| Support: |
Support1: 4.63 Support2: 3.85 |
| Resistance: |
Resistance1: 5.59 Resistance2: 6.18 |
| Pivot: |
5.48  |
| Moving Average: |
MA(5): 5.18  MA(20): 5.34
MA(100): 4.69 MA(250): 4.32 |
| MACD: |
MACD(12,26): 0.08 Signal(9): 0.18 |
| Stochastic oscillator: |
%K(14,3): 16.67 %D(3): 25.39 |
| RSI: |
RSI(14): 44.59 |
| 52-week: |
High: 6.18 Low: 2.40 Change(%): 29.6 |
| Average Vol(K): |
3-Month: 116512 10-Days: 127681 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.AMRX has closed above bottom band by 14.9%. Bollinger Bands are 47.5% wider than normal. The large width of the bands suggest high volatility as compared to AMRX's normal range. The bands have been in this wide range for 11 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 25 Feb 2021
Why Amneal Pharmaceuticals (AMRX) Might Surprise This Earnings Season - Nasdaq
Tue, 23 Feb 2021
Amneal Pharmaceuticals Inc (AMRX) is lower byin a Week, Should You Accumulate? - InvestorsObserver
Mon, 22 Feb 2021
Amneal to Virtually Participate at Upcoming Investor Conferences - Business Wire
Thu, 18 Feb 2021
Analysts Anticipate Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Will Post Quarterly Sales of $502.23 Million - MarketBeat
Thu, 11 Feb 2021
Should You Buy Amneal Pharmaceuticals Inc (AMRX) Stock Thursday? - InvestorsObserver
Wed, 10 Feb 2021
SVB Leerink Comments on Amneal Pharmaceuticals, Inc.'s Q1 2021 Earnings (NYSE:AMRX) - MarketBeat
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers General Specialty & Generic |
| Shares Out. (M) |
148 |
| Shares Float (M) |
94 |
|
% Held by Insiders
|
10.43 |
|
% Held by Institutions
|
69.86 |
|
Shares Short (K)
|
6,090 |
|
Shares Short P. Month (K)
|
6,530 |
Stock Financials |
|
EPS
|
0.418 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.040 |
|
Profit Margin
|
3.30 |
|
Operating Margin
|
7.94 |
|
Return on Assets (ttm)
|
2.4 |
|
Return on Equity (ttm)
|
2.8 |
|
Qtrly Rev. Growth
|
37.3 |
|
Gross Profit (p.s.)
|
3.366 |
|
Sales Per Share
|
12.735 |
|
EBITDA (p.s.)
|
2.568 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
222 |
|
Levered Free Cash Flow (M)
|
75 |
Stock Valuations |
|
PE Ratio
|
11.94 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.45 |
|
Price to Sales
|
0.39 |
|
Price to Cash Flow
|
3.32 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
